Literature DB >> 11118299

EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice.

G Lambert1, J R Bertrand, E Fattal, F Subra, H Pinto-Alphandary, C Malvy, C Auclair, P Couvreur.   

Abstract

EWS Fli-1, a fusion gene resulting from a t(11;22) translocation is found in 90% of both Ewing's sarcoma and primitive neuroectodermal tumor (PNET). In the present study, we show that recently developed polyisobutylcyanoacrylate nanocapsules with an aqueous core were able to encapsulate efficiently high amounts of phosphorothioate oligonucleotides (ODN) directed against EWS Fli-1 chimeric RNA. Release of these ODN in serum medium was shown to be biphasic which was explained by the presence of two types of nanocapsules able to release ODN with different kinetics. In addition, nanocapsules were found to provide protection of these oligonucleotides from the degradation in serum. These ODN nanocapsules permitted to obtain inhibition of Ewing sarcoma-related tumor in mice after intratumoral injection of a cumulative dose as low as 14.4 nanomoles. This new type of non viral vector shows great potential for in vivo administration of oligonucleotides. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118299     DOI: 10.1006/bbrc.2000.3963

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Authors:  Alexandre Prieur; Franck Tirode; Pinchas Cohen; Olivier Delattre
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

Review 2.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 3.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

Review 4.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

Review 5.  Encapsulation of nucleic acids and opportunities for cancer treatment.

Authors:  Lisa Brannon-Peppas; Bilal Ghosn; Krishnendu Roy; Kenneth Cornetta
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

6.  Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells.

Authors:  Benjamin Joachim Schmiedel; Christoph Hutter; Manuela Hesse; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

7.  Chemotherapy in Ewing's sarcoma.

Authors:  Sandeep Jain; Gauri Kapoor
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

8.  Malignant round cell tumor of bone with EWSR1-NFATC2 gene fusion.

Authors:  Navid Sadri; Julieta Barroeta; Svetlana D Pack; Zied Abdullaev; Bishwanath Chatterjee; Raghunath Puthiyaveettil; John S Brooks; Frederic G Barr; Paul J Zhang
Journal:  Virchows Arch       Date:  2014-07-04       Impact factor: 4.064

Review 9.  Ewing's sarcoma: standard and experimental treatment options.

Authors:  Vivek Subbiah; Pete Anderson; Alexander J Lazar; Emily Burdett; Kevin Raymond; Joseph A Ludwig
Journal:  Curr Treat Options Oncol       Date:  2009-06-17

Review 10.  Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities.

Authors:  S A Burchill
Journal:  J Clin Pathol       Date:  2003-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.